Compare MTRX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | GLSI |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.5M | 244.7M |
| IPO Year | 1995 | 2020 |
| Metric | MTRX | GLSI |
|---|---|---|
| Price | $9.89 | $19.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 366.3K | 112.6K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.51 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $873,632,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $9.70 | $7.78 |
| 52 Week High | $15.97 | $34.10 |
| Indicator | MTRX | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 64.93 |
| Support Level | N/A | $17.96 |
| Resistance Level | $12.48 | $19.64 |
| Average True Range (ATR) | 0.38 | 1.08 |
| MACD | -0.05 | 0.34 |
| Stochastic Oscillator | 5.51 | 92.28 |
Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.